Blue­bird forced to halt tri­als af­ter a can­cer-like case, pulls gene ther­a­pies from Eu­rope fol­low­ing pric­ing back­lash — shares slammed

Blue­bird bio halt­ed a tri­al for its gene ther­a­py for a rare neu­ro­log­i­cal dis­ease af­ter find­ing that the treat­ment like­ly caused a can­cer-like con­di­tion in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER